Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder

Neuropsychobiology

Volumn 38, Issue 3, 1998, Pages 119-130

  Xie, Xinmin ^a   Hagan, Russell M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anticonvulsant; Bipolar disorder; Calcium channel; Carbamazepine; Hippocampus; Lamotrigine; Monoamine; Patch clamp recording; Sodium channel; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; CALCIUM CHANNEL; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; PHENYTOIN; PROTEIN KINASE C; SODIUM CHANNEL; VALPROIC ACID;

ACTION POTENTIAL; CONFERENCE PAPER; FOREBRAIN; HIPPOCAMPUS; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MOOD; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY;

ACETIC ACIDS; ACTION POTENTIALS; AMINES; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; CARRIER PROTEINS; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; ION CHANNEL GATING; LIMBIC SYSTEM; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURAL INHIBITION; NEURONAL PLASTICITY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; SODIUM CHANNELS; SYNAPTIC TRANSMISSION; TRIAZINES; VALPROIC ACID;

EID: 0031756758     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026527     Document Type: Conference Paper

References (80)

1. Berrettini WH. Pekkarinen PH: Molecular genetics of bipolar disorder. Ann Med 1996;28:191 194.
2. MacKinnon DF, Jamison KR, DePaulo JR: Genetics of manic depressive illness. Annu Rev Neurosci 1997;20:355 373.
3. Post RM, Weiss SRB, Chuang D-M: Mechanisms of action of anticonvulsants in affective disorders: Comparisons with lithium. J Clin Psychopharmacol 1992;12:23S 35S.
4. Manji KM, Chen G, Hsiao JK, Rishy ED, Masana MI. Potter WZ: Regulation of signal transduction pathways by mood-stabilizing agents: Implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996:57(suppl 13):34-46.
5. Calabrese JR, Bowden CL, Woyshville MJ: Lithium and the anticonvulsants in bipolar disorder; in Bloom FE. Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1994, pp 1099-1111.
6. Post RM, Weiss SRB: The neurobiology of treatment-resistant mood disorders: in Bloom FE. Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995. pp1155 1170.
7. Peck AW: Clinical pharmacology of lamotrigine. Epilepsia 1991;32:S9 S12.
8. Brodie MJ: Lamotrigine. Lancet 1992;339: 1397 1400.
9. Smith D, Chadwick D, Baker G, Davis G. Dewey M: Seizure severity and the quality of life. Epilepsia. 1993;34(suppl 5):S31 35.
10. Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Rhodes L, Keck PE, Bolden-Watson C, Ascher J: Spectrum of activity of lamotrigine in treatment refractory bipolar disorder. Am J Psychiatry 1998;in press.
11. Weisler R, Risner M. Houser T: Use of Lamotrigine in the Treatment of Bipolar Disorder. Am Psychiatry Assoc Meet, Philadelphia, May 21 26, 1994.
12. Walden J, Hesslinger B, van Calker D, Berger M: Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996;29: 193 195.
13. Calabrese J: Lamotrigine in treatment refractory manic depression. Euro Neuropsychopharmacol 1996;6:98 99.
14. Fogelson D, Sternbach H: Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 1997;58:271 273.
15. Mandoki M: Lamotrigine/valproate in treatment resistant bipolar disorder in children and adolescents. Biol Psychiatry 1997;41(suppl 7): 93S 94S.
16. Kusumakar V. Yatham LN: An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997;72:145 148.
17. Sporn J, Sachs G: The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997;17:185 189.
18. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P: Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997;58:12.
19. Calabrese J, Farerri S, Woshville M: Antidepressants effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry 1996;153: 1236.
20. Kusumakar V, Yatham L: Lamotrigine treatment of rapid cycling bipolar disorder Am J Psychiatry 1997;154:1171 1172.
21. Cheung H, Kamp D, Harris E: An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992;13:107 112.
22. Lees G, Leach MJ: Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993;612:190 199.
23. + channels in rat hippocampal neurones. Pflügers Arch 1995;430: 437-446.
24. Xiong ZQ, Stringer JL: Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus. Epilepsy Res 1997;27:187 194.
25. Leach MJ, Baxter MG, Critchley MAE: Neurochemical and behavioural aspects of lamotrigine. Epilepsia 1991;32:S4-S8.
26. Leach MJ, Marden CM, Miller AA: Pharmacological studies of lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986;27: 490-497.
27. Cattenill WA: Cellular and molecular biology of voltage-gated sodium channels. Physiol Rev 1992;72:S15-S48.
28. Catterall WA: Molecular properties of a super-family of plasma-membrane action channels. Curr Opin Cell Biol 1994;6:607 615.
29. Scheuer T, Auld VJ, Boyd S, Offord J, Dunn R, Catterall WA: Functional properties of rat brain sodium channels expressed in a somatic cell line. Science 1990;247:854 858.
30. + channel α subunits stably expressed in a mammalian cell line. J Physiol (Lond) 1997;504P:154P.
31. Rogawski MA, Porter RJ: Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:223 286.
32. + channels. Neuroscience 1996;73:951 962.
33. Zona C, Avoli M: Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 1997;38:522 525.
34. + channels in rat hippocampal neurones. Br J Pharmacol 1997;121:1231 1238.
35. Lang DG, Wang CM, Cooper BR: Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993;266:829 835.
36. + channels expressed in a mammalian cell line. Br Pharmacol Proc 1997;122(suppl):85P.
37. Ruben PC, Starkus JG, Rayner MD: Steady state availability of sodium channels: interactons between slow inactivation and activation. Biophys J 1992;61:941 955.
38. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA: Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994;265:1724 1728.
39. + channel α subunit form part of the receptor site for lamotrigine. Biophysiol J 1998;74:PA399.
40. Eaholtz G, Scheuer T, Catterall WA: Restoration of inactivation and block of open sodium channels by an inactivation gate peptide. Neuron 1994;12:1041 1048.
41. + channels underlies the activity-dependent attenuation of dendritic action potentials in hippocampal CA1 pyramidal neurons. J Neurosci 1997;17:6512 6521.
42. 2+ channels and their possible counterparts in mammalian CNS neurons. Neuropharmacology 1993;32:1075-1088.
43. Coulter DA, Huguenard JR, Prine DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett 1989; 98:74-78.
44. von Wegerer J, Hesslinger B, Berger M, Walden J: A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Fur Neuropsychopharmacol 1997;7:77-81.
45. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW: Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 1996;7:3037 3040.
46. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW: Presynaptic inhibition of excitatory neuro-transmission by lamotrigine in the rat amygdalar neurons. Synapse 1996;24:248 255.
47. 2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996;307:113 116.
48. Calabresi P, Siniscalchi A, Pisani A, Stefani A, Mercuri NB, Bernardi G: A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology 1996;47:557 562.
49. Wang SJ, Tsai JJ, Gean PW: Lamotrigine inhibits tetraethylammonium-induced synaptic plasticity in the rat amygdala. Neuroscience 1997;81:667 671.
50. 2+ channels. J Neurosci 1997;17:3002 3013.
51. Grunze HCR, Greene RW, Möller HJ, Meyer T, Walden J: Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Res 1998;791:330 334.
52. Zona C, Tancredi V, Palma E, Pirrone GC, Avoli M: Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine. Can J Physiol Pharmacol 1990; 68:545 547.
53. Slater GE, Johnston D: Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia 1978;19:379 384.
54. Walden J, Altrup U, Reith H, Speckmann EJ: Effects of valproate on early and late potassium currents of single neurons. Eur Neuropsychopharmacol 1993;3:137 141.
55. Zona C, Avoli M: Effects induced by the antiepileptic drug valproic acid upon the ionic currents in rat neocortical neurons in cell culture. Exp Brain Res 1990;81:313 317.
56. + channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons. Nature 1997;387:869 875.
57. Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ: Charcterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 1984;228:523-530.
58. Wooltorton JR, Mathie A: Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds. Br J Pharmacol 1995;116:2191-200.
59. Southam E, Kirkby D, Higgins GA, Hagan RM: Lamotrigine inhibits 5-hydroxytryplamine uptake in vitro and modulates the p-chloroamphetamine-induced behavioural syndrome in rats. Eur J Pharmacol 1998, in press.
60. + channels in rat sensory neurones by the novel antihypersensitivity agent 4030W92. Br J Pharmacol 1988;124: 953 963.
61. Shibuki K, Okada D: Endogenous nitric oxide release require for long-term synaptic depression in the cerebellum. Nature 1991;349:326 328.
62. Hernández F, Alexander SPH, Kendall DA: Forskolin and 3-isobutyl-1-methylxanthine increase basal and sodium nitroprusside-elevated cyclic GMP levels in adult guinea-pig cerebellar slices. J Neurochem 1994;62:2212 2218.
63. Kennedy SH, Javanmard M, Vaccarino FJ: A review of functional neuroimaging in mood disorders: Positron emission tomography and depression. Can J Psychiatry 1997;42:467 475.
64. Baxter LR Jr, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, Sumida RM: Cerebral metabolic rates for glucose in mood disorders. Studies with position emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry 1985;42:441 447.
65. Goodwin GM, Cavanagh JT, Glabus MF, Kehoe RF, O'Carroll RE, Ebmeier KP: Uptake of 99mTc-exametazime shown by single photon emission computed tomography before and after lithium withdrawal in bipolar patients: Associations with mania. Br J Psychiatry 1997; 170:426-130.
66. Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong L-I., Ho T-H Gutman GA, Crocq M-A, Ranguli R, Nimgaonkar V, Morris-Rosendahl DJ, Gargus JJ: Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: A candidate for schizophrenia and bipolar disorder? Mol Psychiatry 1998;3:32 37.
67. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-827.
68. Willner P: Dopaminergic mechanisms in depression and mania: in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 921 931.
69. Cabib S, Puglisi-Allegra S: Stress, depression and the mesolimbic dopamine system. Psychopharmacology 1996;128:331 342.
70. O'Donnell RA, Miller AA: The effect of lamotrigine upon development of cortical kindled seizures in the rat. Neuropharmacology 1991; 30:253 258.
71. Dalby NO, Nielsen EB: Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 1997;28:63 72.
72. Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT: Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997; 42:851 853.
73. McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF: A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997;9:99 103.
74. Macdonald RL, Kelly KM: Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1986; 35(suppl 4):S41 S50.
75. Wamil AW, McLean MJ: Limitation by gabapentin of high frequency actionpotenial firing by mouse central neurons in cell culture. Epilepsy Res 1994;17:1-11.
76. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC: Mechanism of anticonvulsant aciton of valproate. Prog Neurobiol 1982;19: 315 359.
77. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29: 233 249.
78. Kuo CC, Bean BP: Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol Pharmacol 1994;46:716 725.
79. + channels, expressed in mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol Pharmacol 1991; 40:756 765.
80. Patten SB, Klein GM, Lussier C, Sawa R: Organic mania induced by phenytoin: A case report. Can J Psychiatry 1990;35:457.